Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DARE Daré Bioscience	$2.88 -1.0%	$2.93	$2.67 ▼ $7.56	$25.49M	1.2	38,685 shs	10,783 shs
GRTX Galera Therapeutics	$0.02 +4.9%	$0.03	$0.02 ▼ $0.23	$1.78M	1.77	114,754 shs	54,070 shs
IFRX InflaRx	$1.67 +3.7%	$1.23	$0.82 ▼ $2.82	$112.11M	1.57	230,309 shs	66,294 shs
VSTM Verastem	$7.29 +1.7%	$6.38	$2.10 ▼ $13.52	$375.36M	0.85	1.07 million shs	2.11 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DARE Daré Bioscience	-1.03%	-4.64%	-2.04%	-8.28%	-22.71%
GRTX Galera Therapeutics	+4.89%	-1.26%	-2.07%	-40.40%	-86.60%
IFRX InflaRx	+3.73%	+1.21%	+80.74%	-33.73%	+41.53%
VSTM Verastem	+1.67%	+3.99%	+57.11%	+27.00%	-38.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DARE Daré Bioscience	1.994 of 5 stars	3.3	5.0	0.0	0.0	2.0	0.0	0.0
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	2.54 of 5 stars	3.5	3.0	0.0	0.0	2.6	1.7	0.6
VSTM Verastem	3.1905 of 5 stars	4.5	1.0	0.0	0.0	3.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DARE Daré Bioscience	2.67	Moderate Buy	$24.00	733.33% Upside
GRTX Galera Therapeutics	0.00	N/A	N/A	N/A
IFRX InflaRx	3.00	Buy	$8.50	408.98% Upside
VSTM Verastem	3.00	Buy	$14.33	96.62% Upside

Current Analyst Ratings Breakdown

Latest DARE, VSTM, GRTX, and IFRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
5/8/2025	IFRX InflaRx	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$6.00
4/29/2025	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
4/10/2025	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/9/2025	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
4/1/2025	DARE Daré Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/26/2025	IFRX InflaRx	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/24/2025	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $14.00
3/24/2025	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
3/21/2025	IFRX InflaRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/21/2025	VSTM Verastem	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DARE Daré Bioscience	$9.78K	2,605.07	N/A	N/A	($0.61) per share	-4.72
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	($2.41) per share	N/A
IFRX InflaRx	$165.79K	676.23	N/A	N/A	$1.89 per share	0.88
VSTM Verastem	$10M	37.54	N/A	N/A	$2.27 per share	3.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DARE Daré Bioscience	-$30.16M	-$0.51	N/A	N/A	N/A	-191.65%	N/A	-18.98%	5/13/2025 (Estimated)
GRTX Galera Therapeutics	-$59.08M	-$0.35	N/A	∞	N/A	N/A	N/A	-99.34%	N/A
IFRX InflaRx	-$46.18M	-$0.82	N/A	N/A	N/A	-33,362.70%	-65.98%	-56.86%	N/A
VSTM Verastem	-$87.37M	-$3.50	N/A	N/A	N/A	N/A	-332.73%	-73.97%	N/A

Latest DARE, VSTM, GRTX, and IFRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	DARE Daré Bioscience	-$0.63	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	IFRX InflaRx	-$0.18	-$0.14	+$0.04	-$0.14	$0.03 million	$0.03 million
3/31/2025	Q4 2024	DARE Daré Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million
3/20/2025	Q4 2024	IFRX InflaRx	-$0.27	-$0.09	+$0.18	-$0.09	$0.13 million	N/A
3/20/2025	Q4 2024	VSTM Verastem	-$0.76	-$1.33	-$0.57	-$1.33	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DARE Daré Bioscience	N/A	N/A	N/A	N/A	N/A
GRTX Galera Therapeutics	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DARE Daré Bioscience	N/A	1.14	1.14
GRTX Galera Therapeutics	N/A	9.74	9.74
IFRX InflaRx	N/A	5.31	4.61
VSTM Verastem	2.77	3.23	3.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DARE Daré Bioscience	6.70%
GRTX Galera Therapeutics	50.77%
IFRX InflaRx	42.39%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
DARE Daré Bioscience	4.00%
GRTX Galera Therapeutics	12.90%
IFRX InflaRx	16.30%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DARE Daré Bioscience	30	8.85 million	8.35 million	Not Optionable
GRTX Galera Therapeutics	30	75.46 million	47.38 million	Optionable
IFRX InflaRx	60	67.13 million	56.19 million	Optionable
VSTM Verastem	50	51.49 million	43.53 million	Optionable

DARE, VSTM, GRTX, and IFRX Headlines

Recent News About These Companies

FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type

May 12 at 6:29 PM | pmlive.com

Brokerages Set Verastem, Inc. (NASDAQ:VSTM) Target Price at $13.89

May 12 at 2:13 AM | americanbankingnews.com

Verastem (NASDAQ:VSTM) Given New $14.00 Price Target at HC Wainwright

May 11 at 9:16 AM | marketbeat.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by Brokerages

May 11 at 2:28 AM | marketbeat.com

Balyasny Asset Management L.P. Makes New $20.40 Million Investment in Verastem, Inc. (NASDAQ:VSTM)

May 10 at 5:20 AM | marketbeat.com

Verastem Target of Unusually High Options Trading (NASDAQ:VSTM)

May 10 at 1:29 AM | americanbankingnews.com

FDA Grants Accelerated Approval to Verastem Oncology’s Avmapki Fakzynja Co-Pack for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

May 9, 2025 | pharmexec.com

High-graded low-grade ovarian duo wins for Verastem at FDA

May 9, 2025 | bioworld.com

Verastem Oncology Cancer Drug Combination Gets FDA Approval

May 9, 2025 | marketwatch.com

Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ovarian cancer

May 9, 2025 | fiercepharma.com

Verastem (VSTM) Sees Price Target Increase and FDA Approval Boost | VSTM Stock News

May 9, 2025 | gurufocus.com

FDA nod for first-ever treatment for LGSOC, a rare cancer

May 9, 2025 | thepharmaletter.com

US FDA approves Verastem's ovarian cancer therapy

May 9, 2025 | msn.com

Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update

May 8, 2025 | marketwatch.com

FDA Approves Verastem's Avmapki, Fakzynja Combo for KRAS-Mutant Ovarian Cancer Patients

May 8, 2025 | precisionmedicineonline.com

Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased

May 8, 2025 | msn.com

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer

May 8, 2025 | benzinga.com

Verastem’s Breakthrough FDA Approval and Market Potential for KRAS Mutant LGSOC Therapy

May 8, 2025 | tipranks.com

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025 | businesswire.com

U.S. FDA approves Verastem's cancer therapy

May 8, 2025 | reuters.com

Susquehanna Fundamental Investments LLC Buys New Shares in Verastem, Inc. (NASDAQ:VSTM)

May 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE, VSTM, GRTX, and IFRX Company Descriptions

Daré Bioscience NASDAQ:DARE

$2.88 -0.03 (-1.03%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$2.86 -0.01 (-0.52%)

As of 04:01 AM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Galera Therapeutics NASDAQ:GRTX

$0.02 +0.00 (+4.89%)

As of 05/12/2025 03:04 PM Eastern

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

InflaRx NASDAQ:IFRX

$1.67 +0.06 (+3.73%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$1.60 -0.07 (-4.19%)

As of 05/12/2025 07:23 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Verastem NASDAQ:VSTM

$7.29 +0.12 (+1.67%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$7.12 -0.17 (-2.26%)

As of 04:19 AM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time